Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 1997

View Archived Issues

Yamanouchi's overseas R&D pipeline

R&D at Mitsui Pharmaceuticals

Immunomedics granted Japanese patent for cancer diagnostic technology

Initial clinical results with LGD-1069

Combination of immunosuppression and rhIL-3 for aplastic anemia

AIDS progression and link to chemokine receptors

Sequus seeks FDA approval for new indication of Amphotec

NMDA antagonists claimed by Novartis

Akzo Nobel reveals new dopamine antagonists

Substance P antagonists described by Pfizer

Knoll claims two series of compounds for CNS disorders

Protein tyrosine kinase inhibitors from Glaxo Wellcome

Selective cGMP-PDE inhibitors claimed by Otsuka

The Rockefeller University develops OCD marker

Beth Israel evaluates bFGF for coronary artery disease

Montelukast associated wth bronchodilating effects in asthmatics

Bronchodilating effect of furosemide not secondary to prostaglandin release

First approval for Zomig; antimigraine agents in development

MP-52 enters clinic

Anticancer agent from Banyu heading for clinic

NM-702 enters phase II trials

Therics receives SBIR grant for ocular drug delivery R&D

MGI Pharma and Schein reach marketing agreement for INFeD

Astra Merck launches Lexxel in U.S.

MRC, Sankyo and Oncogene Science to develop new antiflu drugs

BBI Pharmaceuticals to fund phase I trial with soybean extract in BPH

NanoSystems and Astra Draco collaborate for respiratory disorders

Water-soluble HIV protease inhibitor from Sankyo

Advanced Viral Research and the NCI sign genetic research agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.